Post-operative pain drug Nocita expected to begin generating widespread sales, says William Blair
William Blair analyst Y. Katherine Xu remains on the sidelines with shares of Tokai Pharmaceuticals, Inc.
Friday morning before market open, Bristol-Myers Squibb Co (NYSE:BMY) came to terms with the failure of its Phase III CheckMate-026 trial evaluating Opdivo …
William Blair analyst Jason Ader weighs in on Microsoft Corporation (NASDAQ:MSFT) following a solid fiscal fourth quarter for the company. Microsoft reported revenue that crushed …
William Blair analysts discuss biotech companies SAGE Therapeutics Inc (NASDAQ:SAGE) and EXACT Sciences Corporation (NASDAQ:EXAS) after developments that will improve the company’s future outlook. …
Facebook Inc In anticipation of Facebook Inc (NASDAQ:FB)’s earnings release, due after market close on July 27, William Blair analyst, Ralph Schackart, weighed …
There is nowhere for companies to hide with markets plunging following Brexit. Analyst Nicholas Heymann of William Blair discusses why General Electric Company …
William Blair analyst Brian Weinstein chimed in today on Sequenom, Inc. (NASDAQ:SQNM), following the news that the Supreme Court rejected Sequenom’s appeal of a prior ruling invalidating …
In a research report issued Friday, William Blair analyst Tim Lugo reiterated a Market Perform rating on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), after …
Healthcare analysts are optimistic on both ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Celgene Corporation (NASDAQ:CELG) as ACADIA’s primary commercialized product received positive coverage and …
